0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Treatment of Shigellosis: III. Comparison of One- or Two-Dose Ciprofloxacin with Standard 5-Day Therapy: A Randomized, Blinded Trial

Michael L. Bennish, MD; Mohammed Abdus Salam, MB, BS; Wasif Ali Khan, MB, BS; and Ali Miraj Khan, MB, BS
[+] Article and Author Information

Grant Support: By a grant from Bayer, Leverkusen, Germany, and by the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). The ICDDR,B is funded by countries and agencies that share its concern for the health problems of developing countries. Current donors include the aid agencies of the governments of Australia, Bangladesh, Belgium, Canada, Denmark, France, Japan, The Netherlands, Norway, Sweden, Switzerland, the United Kingdom, and the United States; the United Nations Development Program and UNICEF; and the Ford and Sasakawa Foundations. Dr. Bennish is supported by a grant from the Applied Diarrheal Disease Research Project of the United States Agency for International Development.

Requests for Reprints: Michael Bennish, MD, New England Medical Center, 750 Washington Street, Box 041, Boston, MA 02111.

Current Author Addresses: Dr. Bennish, New England Medical Center, 750 Washington Street, Box 041, Boston, MA 02111.

Drs. Salam, W. Khan, and A. Khan: International Centre for Diarrhoeal Disease Research, Bangladesh, GPO Box 128, Dhaka 1000, Bangladesh.


© 1992 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1992;117(9):727-734. doi:10.7326/0003-4819-117-9-727
Text Size: A A A

Objective: To determine whether a single dose, or 2 doses, of ciprofloxacin are as effective as 5-day, 10-dose therapy for the treatment of shigellosis in adult men who are moderately to severely ill.

Design: Randomized, double-blind clinical trial.

Setting: A diarrhea treatment center in the capital city of a developing country, Bangladesh.

Patients: A total of 128 adult men with dysentery of less than 96 hours duration. All had Shigella organisms isolated from a culture of stool.

Interventions: Patients were randomly assigned to receive either a single 1-gram dose of ciprofloxacin at admission to the study (single-dose group; n = 40), a 1-gram dose of ciprofloxacin at admission and 24 hours later (2-dose group; n = 43), or 500 mg of ciprofloxacin every 12 hours for 5 days (10 dose group; n = 35). All patients were hospitalized for 6 days.

Measurements: Stools were collected individually; their character and consistency were recorded and cultured daily. A physical examination and recording of symptoms were done daily, and the temperature was measured every 4 hours. Therapy was considered to have failed in patients who did not have improvement in the signs and symptoms of dysentery after 72 hours of therapy or in patients who on study day 5 had more than nine stools, or more than two watery stools, or were febrile.

Results: There were no treatment failures in the 78 patients infected with species of Shigella other than Shigella dysenteriae type 1. Among the 40 patients infected with S. dysenteriae type 1, treatment failed in 4 of the 10 patients who received single-dose therapy, 2 of the 15 patients who received 2-dose therapy, and none of the 15 patients who received 10-dose therapy (P = 0.017, single-dose therapy group compared with 10-dose group; P= 0.15 for the single-dose group compared with the 2-dose group; P > 0.2 for the 2-dose group compared with the 10-dose group).

Conclusions: A single 1-gram dose of ciprofloxacin is effective therapy for patients infected with species of Shigella other than S. dysenteriae type 1. Single-dose therapy is inferior to 10-dose therapy for treating patients infected with S. dysenteriae type 1.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)